News Coverage 10.20.20 Share on Twitter Share on Facebook Share on LinkedIn The international neoantigen initiative Tumour Neoantigen Selection Alliance (TESLA) has identified key parameters for immunotherapy advancement. Related Announcement, Press Release PICI Welcomes Aimee Johnson as Chief Marketing Officer Announcement, Press Release PICI Network Shapes Future of Immunotherapy at AACR 202 Announcement, Press Release PICI and CVC Unite to Accelerate Cancer Vaccines